Impact of Cardiac Resynchronization Therapy on Mortality: What Do We Expect from Ongoing Trials?
Cardiac resynchronization therapy (CRT), a device-based therapy applied in the context of continuing conventional medical treatment for patients with advanced heart failure (HF) and dyssynchronous left-ventricular (LV) contraction, improves cardiac function and quality of life, but its effects on mortality were uncertain until 2003.
KeywordsCardiac Resynchronization Therapy Advanced Heart Failure Heart Failure Trial Optimal Medical Treatment Conventional Medical Treatment
Unable to display preview. Download preview PDF.
- 2.US Food and Drug Administration (2002) Summary of safety and effectiveness: Guidant Contak CD CRT-D system (report). Available at http://www.fda.gov/cdrh/pdf/p010012.html
- 3.US Food and Drug Administration (2002) Summary of safety and effectiveness: Medtronic Insync ICD Model 7272 (report). Available at http://www.fda.gov/ohrms/dockets/ac/02/briefing/3843b2.htm
- 6.Bristow MR, Saxon LA, Boehmer JP et al (2003) Cardiac resynchronization therapy reduces hospitalization and cardiac resynchronization therapy and an implantable defibrillator reduces mortality in chronic heart failure: results of the COMPANION trial. Paper presented at: American College of Cardiology 52nd Annual Scientific Session, 30 March to 2 April 2003, ChicagoGoogle Scholar
- 7.Young JB, Abraham WT, Smith AL et al (2003) Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced heart failure. The MIRACLE ICD Trial. JAMA 289:2685–2694Google Scholar